anti-DLL3 fusion albumin-drug conjugate (IntoCell/Y-Biologics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-DLL3 fusion albumin-drug conjugate (IntoCell/Y-Biologics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionDelta-like protein 3 modulators
TargetsDelta-like protein 3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIntoCell Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIntoCell IncY-biologics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A